XOMA Royalty Corporation Quarterly report [Sections 13 or 15(d)]

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Dare (Details)

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Dare (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Apr. 30, 2024	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Agreements
Payments of consideration under RPAs, AAAs and CPPAs		$ 8,000	$ 15,000
Long-term royalty and commercial payment receivables under the cost recovery method		59,916		$ 55,936
Short-term royalty and commercial payment receivables under the cost recovery method		413		413
Royalty Purchase Agreement \| Dare
Agreements
Payments of consideration under RPAs, AAAs and CPPAs	$ 22,000
Percentage of remaining royalties	100.00%
Payable on milestone	$ 11,000
Specified amount of each successive receipt that requires milestone payment	22,000
Return threshold	88,000
Long-term royalty and commercial payment receivables under the cost recovery method	$ 22,000
Short-term royalty and commercial payment receivables under the cost recovery method		0
Allowance for credit losses		$ 0		$ 0
Royalty Purchase Agreement \| Dare \| OVAPRENE
Agreements
Royalties entity has right to receive (as a percent)	4.00%
Royalty Purchase Agreement \| Dare \| OVAPRENE \| Upon achievement of a pre-specified return threshold
Agreements
Royalties entity has right to receive (as a percent)	2.50%
Royalty Purchase Agreement \| Dare \| Sildenafil Cream
Agreements
Royalties entity has right to receive (as a percent)	2.00%
Royalty Purchase Agreement \| Dare \| Sildenafil Cream \| Upon achievement of a pre-specified return threshold
Agreements
Royalties entity has right to receive (as a percent)	1.25%